{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:12:40Z","timestamp":1792548760915,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00259-019-04432-2","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T05:12:17Z","timestamp":1563858737000},"page":"2280-2288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["The use of 68Ga-PET\/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3657-9718","authenticated-orcid":false,"given":"Sheliyan","family":"Raveenthiran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Yaxley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"4432_CR1","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00345-018-2342-3","volume":"36","author":"SH Rossi","year":"2018","unstructured":"Rossi SH, Prezzi D, Kelly-Morland C, Goh V. Imaging for the diagnosis and response assessment of renal tumours. World J Urol. 2018;36:1927\u201342. \n                    https:\/\/doi.org\/10.1007\/s00345-018-2342-3\n                    \n                  .","journal-title":"World J Urol"},{"key":"4432_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nrurol.2010.63","volume":"7","author":"MJ Leveridge","year":"2010","unstructured":"Leveridge MJ, Bostrom PJ, Koulouris G, Finelli A, Lawrentschuk N. Imaging renal cell carcinoma with ultrasonography, CT and MRI. Nat Rev Urol. 2010;7:311\u201325. \n                    https:\/\/doi.org\/10.1038\/nrurol.2010.63\n                    \n                  .","journal-title":"Nat Rev Urol"},{"key":"4432_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12149-017-1216-x","volume":"32","author":"SP Campbell","year":"2018","unstructured":"Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, et al. Low levels of PSMA expression limit the utility of F-18-DCFPyL PET\/CT for imaging urothelial carcinoma. Ann Nucl Med. 2018;32:69\u201374. \n                    https:\/\/doi.org\/10.1007\/s12149-017-1216-x\n                    \n                  .","journal-title":"Ann Nucl Med"},{"key":"4432_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.urology.2007.03.025","volume":"70","author":"A Baccala","year":"2007","unstructured":"Baccala A, Sercia L, Li J, Heston W, Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology. 2007;70:385\u201390.","journal-title":"Urology"},{"key":"4432_CR5","doi-asserted-by":"publisher","unstructured":"Evangelista L, Basso U, Maruzzo M, Novara G. The role of radiolabeled prostate-specific membrane antigen positron emission tomography\/computed tomography for the evaluation of renal cancer. Eur Urol Focus. 2018. \n                    https:\/\/doi.org\/10.1016\/j.euf.2018.08.004\n                    \n                  .","DOI":"10.1016\/j.euf.2018.08.004"},{"key":"4432_CR6","doi-asserted-by":"publisher","first-page":"111073","DOI":"10.18632\/oncotarget.22441","volume":"8","author":"MA Hoffmann","year":"2017","unstructured":"Hoffmann MA, Miederer M, Wieler HJ, Ruf C, Jakobs FM, Schreckenberger M. Diagnostic performance of 68Gallium-PSMA-11 PET\/CT to detect significant prostate cancer and comparison with 18FEC PET\/CT. Oncotarget. 2017;8:111073\u201383. \n                    https:\/\/doi.org\/10.18632\/oncotarget.22441\n                    \n                  .","journal-title":"Oncotarget"},{"key":"4432_CR7","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.2214\/AJR.11.7790","volume":"199","author":"K Zukotynski","year":"2012","unstructured":"Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Krajewski K, et al. PET\/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012;199:W163\u20137.","journal-title":"AJR Am J Roentgenol"},{"key":"4432_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00259-014-2766-y","volume":"41","author":"E Demirci","year":"2014","unstructured":"Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, et al. Ga-68-PSMA PET\/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:1461\u20132. \n                    https:\/\/doi.org\/10.1007\/s00259-014-2766-y\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4432_CR9","doi-asserted-by":"publisher","first-page":"E261","DOI":"10.1097\/RLU.0000000000001128","volume":"41","author":"I Einspieler","year":"2016","unstructured":"Einspieler I, Tauber R, Maurer T, Schwaiger M, Eiber M. Ga-68 prostate-specific membrane antigen uptake in renal cell cancer lymph node metastases. Clin Nucl Med. 2016;41:E261\u2013E2. \n                    https:\/\/doi.org\/10.1097\/rlu.0000000000001128\n                    \n                  .","journal-title":"Clin Nucl Med"},{"key":"4432_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eucr.2017.09.010","volume":"16","author":"S Saadat","year":"2018","unstructured":"Saadat S, Tie B, Wood S, Vela I, Rhee H. Imaging tumour thrombus of clear cell renal cell carcinoma: FDG PET or PSMA PET? Direct in vivo comparison of two technologies. Urology Case Reports. 2018;16:4\u20135. \n                    https:\/\/doi.org\/10.1016\/j.eucr.2017.09.010\n                    \n                  .","journal-title":"Urology Case Reports"},{"key":"4432_CR11","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1097\/RLU.0000000000001394","volume":"41","author":"A Sasikumar","year":"2016","unstructured":"Sasikumar A, Joy A, Nanabala R, Unni M, Tk P. Complimentary pattern of uptake in 18F-FDG PET\/CT and 68Ga-prostate-specific membrane antigen PET\/CT in a case of metastatic clear cell renal carcinoma. Clin Nucl Med. 2016;41:e517\u2013e9.","journal-title":"Clin Nucl Med"},{"key":"4432_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40336-018-0286-7","volume":"6","author":"L Evangelista","year":"2018","unstructured":"Evangelista L, Cuppari L. 18F-FDG or 68Ga\/18F-PSMA PET\/CT in recurrent renal cancer? Clinical and Translational Imaging. 2018;6:329\u201330. \n                    https:\/\/doi.org\/10.1007\/s40336-018-0286-7\n                    \n                  .","journal-title":"Clinical and Translational Imaging"},{"key":"4432_CR13","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/1754-9485.12590","volume":"61","author":"S Siva","year":"2017","unstructured":"Siva S, Callahan J, Pryor D, Martin J, Lawrentschuk N, Hofman MS. Utility of 68Ga prostate specific membrane antigen \u2013 positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. J Med Imaging Radiat Oncol. 2017;61:372\u20138. \n                    https:\/\/doi.org\/10.1111\/1754-9485.12590\n                    \n                  .","journal-title":"J Med Imaging Radiat Oncol"},{"key":"4432_CR14","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/RLU.0000000000000875","volume":"40","author":"M Takahashi","year":"2015","unstructured":"Takahashi M, Kume H, Koyama K, Nakagawa T, Fujimura T, Morikawa T, et al. Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT. Clin Nucl Med. 2015;40:936\u201340.","journal-title":"Clin Nucl Med"},{"key":"4432_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5489\/cuaj.10196","volume":"5","author":"JH Pinthus","year":"2011","unstructured":"Pinthus JH, Whelan KF, Gallino D, Lu J-P, Rothschild N. Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications. Can Urol Assoc J. 2011;5:274\u201382. \n                    https:\/\/doi.org\/10.5489\/cuaj.10196\n                    \n                  .","journal-title":"Can Urol Assoc J"},{"key":"4432_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/ajco.12635_3","volume":"12","author":"H Rhee","year":"2016","unstructured":"Rhee H, Tham CM, Blazak J, Ng KL, Thomas P, Vela I, et al. Staging advanced and metastatic clear cell renal cell carcinoma with 68-gallium PSMA PET for treatment planning. Asia Pac J Clin Oncol. 2016;12:48.","journal-title":"Asia Pac J Clin Oncol"},{"key":"4432_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0090-4295(00)01094-3","volume":"57","author":"SS Chang","year":"2001","unstructured":"Chang SS, Reuter VE, Heston WD, et al. Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology. 2001;57:801.","journal-title":"Urology"},{"key":"4432_CR18","first-page":"1","volume":"13","author":"G Li","year":"2003","unstructured":"Li G, Lambert C, Gentil-Perret A, et al. Molecular and cytometric analysis of renal cell carcinoma cells. Concepts, techniques and prospects. Prog Urol. 2003;13:1.","journal-title":"Prog Urol"},{"key":"4432_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/modpathol.2008.42","volume":"21","author":"HA Al-Ahmadie","year":"2008","unstructured":"Al-Ahmadie HA, Olgac S, Gregor PD, et al. Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol. 2008;21:727.","journal-title":"Mod Pathol"},{"key":"4432_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00259-016-3360-2","volume":"44","author":"LM Sawicki","year":"2017","unstructured":"Sawicki LM, Buchbender C, Boos J, Giessing M, Ermert J, Antke C, et al. Diagnostic potential of PET\/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging. 2017;44:102\u20137. \n                    https:\/\/doi.org\/10.1007\/s00259-016-3360-2\n                    \n                  .","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04432-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04432-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,21]],"date-time":"2020-07-21T23:27:08Z","timestamp":1595374028000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04432-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4432"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04432-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"6 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethics approval was obtained from the Royal Brisbane and Women\u2019s Hospital Human Research Ethics Committee ref.: HREC\/18\/QRBW\/395 (ERM: 42076).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and approval to publish"}},{"value":"The authors have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}